Abstract
Apixaban is a new oral anticoagulant (NOACs: Novel Oral Anticoagulant), like dabigatran, rivaroxaban, and edoxaban. All of them are prescribed to patients with non valvular atrial fibrillation or venous thromboembolism, to replace warfarin, because of the lower probability of bleeding, however they can cause bleeding by themselves. Bleeding is an adverse event in patients taking anticoagulants. It is associated with a significant increase of morbidity and risk of death. However, these drugs should be used only for the time when anticoagulation is strictly required, especially when used for preventing deep vein thrombosis. Prolonged use increases the risk of bleeding. In the ARISTOTLE Trial Apixaban, compared with warfarin, was associated with a lower rate of intracranial hemorrhages and less adverse consequences following extracranial hemorrhage. Many physicians still have limited experience with new oral anticoagulants and about bleeding risk managment. We reviewed the available literature on extracranial and intracranial bleeding concerning apixaban.
Keywords: Apixaban, extracranial, intracranial bleeding, anticoagulant, thrombosis, artial fibrillation.
Current Drug Targets
Title:To Bleed or Not to Bleed: That is the Question. The Side Effects of Apixaban
Volume: 19 Issue: 6
Author(s): Marco Matteo Ciccone*, Annapaola Zito, Fiorella Devito, Maria Maiello and Pasquale Palmiero
Affiliation:
- Cardiovascular Diseases Section, Department of Emergency and Organ Transplantation (DETO), University of Bari,Italy
Keywords: Apixaban, extracranial, intracranial bleeding, anticoagulant, thrombosis, artial fibrillation.
Abstract: Apixaban is a new oral anticoagulant (NOACs: Novel Oral Anticoagulant), like dabigatran, rivaroxaban, and edoxaban. All of them are prescribed to patients with non valvular atrial fibrillation or venous thromboembolism, to replace warfarin, because of the lower probability of bleeding, however they can cause bleeding by themselves. Bleeding is an adverse event in patients taking anticoagulants. It is associated with a significant increase of morbidity and risk of death. However, these drugs should be used only for the time when anticoagulation is strictly required, especially when used for preventing deep vein thrombosis. Prolonged use increases the risk of bleeding. In the ARISTOTLE Trial Apixaban, compared with warfarin, was associated with a lower rate of intracranial hemorrhages and less adverse consequences following extracranial hemorrhage. Many physicians still have limited experience with new oral anticoagulants and about bleeding risk managment. We reviewed the available literature on extracranial and intracranial bleeding concerning apixaban.
Export Options
About this article
Cite this article as:
Ciccone Matteo Marco*, Zito Annapaola, Devito Fiorella, Maiello Maria and Palmiero Pasquale, To Bleed or Not to Bleed: That is the Question. The Side Effects of Apixaban, Current Drug Targets 2018; 19 (6) . https://dx.doi.org/10.2174/1389450116666151001113932
DOI https://dx.doi.org/10.2174/1389450116666151001113932 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
Therapeutic Chemical and RNA Design with Artificial Intelligence
Computer-Aided Drug Design (CADD) has emerged as a fundamental component of modern drug discovery. Molecular docking facilitates virtual screening on a large scale through structural simulations. However, traditional CADD approaches face significant limitations, as they can only screen known compounds from existing libraries. PubChem, as the most widely used chemical ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Biosynthesis and Metabolic Engineering of Anthocyanins in Arabidopsis thaliana
Recent Patents on Biotechnology Is Relief from Diabetes Just a Breath Away … ?
Current Drug Delivery Neuroferritinopathy: Update on Clinical Features and Pathogenesis
Current Drug Targets A Nanoparticle-Encapsulated Non-Nucleoside Reverse-Transcriptase Inhibitor with Enhanced Anti-HIV-1 Activity and Prolonged Circulation Time in Plasma
Current Pharmaceutical Design Active Targeting Strategies for Anticancer Drug Nanocarriers
Current Drug Delivery CD248: Reviewing its Role in Health and Disease
Current Drug Targets Targeting the Acute Myeloid Leukemia Stem Cells
Anti-Cancer Agents in Medicinal Chemistry The Heat Shock Connection of Metabolic Stress and Dietary Restriction
Current Pharmaceutical Biotechnology Therapeutic Potential of Hammerhead Ribozymes in the Treatment of Hyper-Proliferative Diseases
Current Pharmaceutical Biotechnology Characterization of Bovine Tau-Preparations by Two-Dimensional Gel Electrophoresis
Protein & Peptide Letters Heat Shock Proteins and Ion Channels. Functional Interactions and Therapeutic Consequences
Current Pharmaceutical Biotechnology Travelers’ Diarrhea: A Clinical Review
Recent Patents on Inflammation & Allergy Drug Discovery miRNAs Highlights in Stem and Cancer Cells
Mini-Reviews in Medicinal Chemistry Glucocorticoid Excess Induces Accumulation of Cardiac Glycogen and Triglyceride: Suggested Role for AMPK
Current Pharmaceutical Design The Pharmacokinetics of Long-Acting Antipsychotic Medications
Current Clinical Pharmacology The Use of Transient Expression Systems for the Rapid Production of Virus-like Particles in Plants
Current Pharmaceutical Design Recent Patents on Ocular Drug Delivery Systems
Recent Patents on Drug Delivery & Formulation Endothelin-1 and Endothelin Converting Enzyme-1 in Human Atherosclerosis - Novel Targets for Pharmacotherapy in Atherosclerosis
Current Vascular Pharmacology Pathobiology of Pulmonary Arterial Hypertension
Current Respiratory Medicine Reviews Targeting the Arrhythmogenic Substrate in Atrial Fibrillation: Focus on Structural Remodeling
Current Drug Targets